Singapore, Sept. 8 -- Taiwan-based Horien Biochemical Technology has announced a major double milestone in its global expansion strategy, i.e. the formal entry into the Thai market following Thai Food and Drug Administration (Thai FDA) Class 4 approvals for three advanced regenerative medical devices (Collagen Bone Graft Matrix; Collagen Matrix and Extracellular Membrane), alongside securing a prestigious US invention patent for its innovative biodegradable ureteral stent.

With its regulatory foundation fully established in Thailand, Horien is actively inviting qualified exclusive and strategic distribution partners to drive responsible market launch, clinician education, and long-term healthcare infrastructure development across the cou...